NCT03217396 · RECRUITING
Biomarkers of Synaptic Damage in Multiple Sclerosis
This study is collecting blood and spinal fluid samples from people with multiple sclerosis, ALS, Alzheimer's disease, and Parkinson's disease to look for biological markers of nerve damage. It is an observational cohort study, not a drug or treatment trial, meaning no intervention is being tested. People with these conditions, along with healthy volunteers, are being followed over roughly five years. Details on current enrollment status are limited.
You may qualify if
- Male and female patients (age between 18 and 65 years)
- Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
- EDSS between 0 and 5.5 (included),
- Patients able to provide informed consent to participation in the study
You're excluded if
- Inability to provide informed written consent
- Altered basal blood count
- Pregnancy or lactation
- Contraindications for the execution of magnetic resonance imaging with gadolinium
- Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2022-10-28